Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 21:2020:6138132.
doi: 10.1155/2020/6138132. eCollection 2020.

Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment

Affiliations
Review

Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment

Barbara Cvenkel et al. J Ophthalmol. .

Abstract

Glaucoma is a neurodegenerative disease characterized by progressive loss of retinal ganglion cells and their axons. Lowering of intraocular pressure (IOP) is currently the only proven treatment strategy for glaucoma. However, some patients show progressive loss of visual field and quality of life despite controlled IOP which indicates that other factors are implicated in glaucoma. Therefore, approaches that could prevent or decrease the rate of progression and do not rely on IOP lowering have gained much attention. Effective neuroprotection has been reported in animal models of glaucoma, but till now, no neuroprotective agents have been clinically approved. The present update provides an overview of currently available IOP-lowering medications. Moreover, potential new treatment targets for IOP-lowering and neuroprotective therapy are discussed. Finally, future trends in glaucoma therapy are addressed, including sustained drug delivery systems and progress toward personalized medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding this work.

Similar articles

Cited by

References

    1. Flaxman S. R., Bourne R. R. A., Resnikoff S., et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. The Lancet Global Health. 2017;5(12):e1221–e1234. doi: 10.1016/s2214-109x(17)30393-5. - DOI - PubMed
    1. Tham Y.-C., Li X., Wong T. Y., Quigley H. A., Aung T., Cheng C.-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. doi: 10.1016/j.ophtha.2014.05.013. - DOI - PubMed
    1. Peters D., Bengtsson B., Heijl A. Lifetime risk of blindness in open-angle glaucoma. American Journal of Ophthalmology. 2013;156(4):724–730. doi: 10.1016/j.ajo.2013.05.027. - DOI - PubMed
    1. Yadav K. S., Rajpurohit R., Sharma S. Glaucoma: current treatment and impact of advanced drug delivery systems. Life Sciences. 2019;221:362–376. doi: 10.1016/j.lfs.2019.02.029. - DOI - PubMed
    1. Mozaffarieh M., Flammer J. New insights in the pathogenesis and treatment of normal tension glaucoma. Current Opinion in Pharmacology. 2013;13(1):43–49. doi: 10.1016/j.coph.2012.10.001. - DOI - PubMed

LinkOut - more resources